A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 [vandetanib] in Combination With Docetaxel (Taxotere) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Docetaxel (Primary) ; Vandetanib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 08 Apr 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.com.
- 06 Jul 2007 New trial record.